Literature DB >> 18422787

Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.

Paolo Prandoni1, Michel M Samama.   

Abstract

Acute venous thromboembolism (VTE) is a serious and potentially fatal disorder, which often complicates the course of hospitalized medical patients. This is particularly true for carriers of malignant diseases. While the introduction of thromboprophylactic measures has probably affected the occurrence of postoperative VTE, there is an increasing awareness of the importance of medical conditions in determining thromboembolic events. Simple and clinically relevant risk assessment models are available to facilitate VTE risk assessment in hospitalized medical patients. Their validation in prospective studies is in progress. Randomized controlled clinical trials have consistently documented the efficacy of heparins and fondaparinux for prevention of VTE in hospitalized medical patients with a minimal haemorrhagic risk. Recognition of the incidence and clinical importance of thrombosis will probably encourage more widespread use of antithrombotic prophylaxis in medical patients and especially in some particular types of malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422787     DOI: 10.1111/j.1365-2141.2008.07089.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Authors:  Megan K Yee; Tarek Nafee; Yazan Daaboul; Serge Korjian; Fahad AlKhalfan; Mathieu Kerneis; Cara Wiest; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alexander T Cohen; Robert A Harrington; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

2.  Venous thromboembolism in colorectal surgery: skip SCIP or comply?

Authors:  H H Erem; R P Kiran; F H Remzi; J D Vogel
Journal:  Tech Coloproctol       Date:  2014-02-22       Impact factor: 3.781

3.  Characterization of Venous Thromboembolism Risk in Medical Inpatients Using Different Clinical Risk Assessment Models.

Authors:  Reza Rafizadeh; Ricky D Turgeon; Josh Batterink; Victoria Su; Anthony Lau
Journal:  Can J Hosp Pharm       Date:  2016-12-23

Review 4.  Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors:  Hikmat Abdel-Razeq; Asem Mansour
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

5.  Implementing thrombosis guidelines in cancer patients: a review.

Authors:  Dominique Farge-Bancel; Henri Bounameaux; Benjamin Brenner; Harry R Büller; Ajay Kakkar; Ingrid Pabinger; Michael Streiff; Philippe Debourdeau
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

6.  Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization.

Authors:  Stefan Hohaus; Maria Chiara Tisi; Francesca Bartolomei; Annarosa Cuccaro; Elena Maiolo; Eleonora Alma; Francesco D'Alò; Silvia Bellesi; Elena Rossi; Valerio De Stefano
Journal:  Blood Cancer J       Date:  2018-06-07       Impact factor: 11.037

7.  Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records.

Authors:  O Lavon; T Tamir
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

8.  Prophylaxis of venous thromboembolism in medical patients: too much or too little?

Authors:  Christian Fynbo Christiansen
Journal:  Clin Epidemiol       Date:  2012-11-15       Impact factor: 4.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.